Stereotaxis: Green Shoots Turn to a Catheter-Driven Inflection as Recurring Revenue Crosses $6M
Q2 2026 shows proprietary catheter adoption scaling, new system launches (Synchrony, GenesisX), and a path to cash-flow profitability by H1 2027.
STXS · Earnings Call · 2026-08-11
A Commercial Inflection Amid a Weak Tape
Stereotaxis’ Q2 2026 report came at a time when the market was questioning the company’s ability to convert a stacked regulatory pipeline into commercial traction. The stock has been under pressure, down ~24% over the last 90 days and still ~32% below its May peak, but the numbers tell a different story underneath. Management framed the quarter as the moment initial green shoots of commercial success became visible, with recurring revenue surpassing $6 million and robotic catheter revenue growing nearly 300% sequentially. CFO Kimberly Peery noted, “Recurring revenue in the quarter reflects a significant increase in revenue from our new portfolio of robotically navigated catheters, up 270% sequentially and 450% year-over-year.” — Kimberly Peery, Chief Financial Officer · 2026-08-11 The catalyst is the MAGiC catheter, the first proprietary ablation catheter in two decades. Physician feedback has been unusually strong. CEO David Fischel quoted one user: “MAGiC performs so much better than the old ablation catheter... It fundamentally changes the utility of the Stereotaxis system, more than doubling the value of having a robot.” — David Fischel, Chief Executive Officer · 2026-08-11 This enthusiasm is translating into order momentum, and the company now sees a clear runway for Recurring revenue to grow to ~$7M in Q3 and ~$8M in Q4 of this year.Supply Constrained, But Manufacturing Ramping
The main bottleneck is no longer demand but production. The company is working with contract manufacturer Osypka to ramp output, and catheters remain on backlog. Fischel explained, “We are still supply constrained. We have a backlog of catheter orders from customers... as we get catheters in from that supply, we're able to ship it kind of very quickly to customers and recognize revenue.” — David Fischel, Chief Executive Officer · 2026-08-11 Management guided to ~$1M incremental catheter revenue per quarter for the next couple of quarters, with significantly more opportunity in 2027 as capacity expands and the majority of the installed base converts away from the Johnson & Johnson catheter. This transition is a strategic shift from the old “razor-razorblade” model to a fully owned razor and blade ecosystem. The recurring revenue gross margin of 66% is already attractive, but management expects mid-70s margins as volumes scale. Gross margin of 58% in Q2 reflects low manufacturing volumes, with recurring revenue margins at 66% and systems at 29%. The company sees significant leverage in 2027-2028 as fixed costs spread over a larger base.System Revenue: Synchrony and GenesisX
Beyond catheters, two new system platforms are contributing. Synchrony, the digital cockpit for the robotic suite, received FDA clearance in Q2 and has begun shipping, with several systems already in daily clinical use. Fischel noted, “We expect the second half to be stronger with approximately $3 million in each of the third and fourth quarters” — David Fischel, Chief Executive Officer · 2026-08-11 of system revenue, split between Synchrony and robotic systems. The first U.S. GenesisX purchase was announced from an academic medical center, with installation expected this fall using a non-modified X-ray from a major manufacturer—a key proof point for the compatibility statement strategy that could unlock a much larger addressable market.Pipeline and Path to Profitability
The innovation engine remains robust. The Robocath acquisition closed in July, adding a complementary endovascular robotic platform. First-in-human procedures for MAGiC with pulsed field ablation are planned before year-end. On the financial side, the company is modeling to achieve cash flow profitability in the first half of 2027, with minimal assumptions on the capital side. Fischel emphasized,This aligns with prior calls where management stressed a disciplined expense base. As one analyst noted in a prior quarter, “our expectation is that operating expenses will overall be flat.” — David Fischel, Chief Executive Officer · 2026-03-09 The combination of a monetized catheter portfolio, a workflow/software (Synchrony), and a versatile robot (GenesisX) shifts the narrative from development-stage to early commercialization. The market may still be pricing in execution risk, but the data increasingly points to a company on the cusp of a significant revenue and margin inflection.It requires relatively modest assumptions to get to breakeven. We are obviously staying lean on our operating expenses... and then letting the recurring revenue start to kind of incrementally grow with that.